MENU
NEWSLETTERS
MENU
SECTIONS
OTHER
CLASSIFIEDS
CONTACT US / FAQ
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Articles published by Avalyn Pharma Inc.

< Previous 1 2 Next >
News headline image
Avalyn Reports First Quarter 2026 Financial Results and Recent Business Highlights
From Avalyn Pharma Inc.
Via GlobeNewswire
Tickers AVLN
News headline image
Avalyn to Participate in the Jefferies Global Healthcare Conference
From Avalyn Pharma Inc.
Via GlobeNewswire
Tickers AVLN
News headline image
Avalyn Announces Additional Long-term Data on AP01, Inhaled Pirfenidone, for the Treatment of Pulmonary Fibrosis to be Presented at the European Alliance of Associations for Rheumatology 2026
From Avalyn Pharma Inc.
Via GlobeNewswire
Tickers AVLN
News headline image
Avalyn to Present Patient-Centered Research on AP01 Delivery and Supportive Care Experiences at American Thoracic Society 2026 International Conference
From Avalyn Pharma Inc.
Via GlobeNewswire
Tickers AVLN
News headline image
Avalyn Announces Pricing of Upsized Initial Public Offering
From Avalyn Pharma Inc.
Via GlobeNewswire
News headline image
Avalyn Strengthens Leadership Team to Support Long-Term Growth with Appointments of Industry Leaders Adam Golden and Frank Salisbury
From Avalyn Pharma Inc.
Via GlobeNewswire
News headline image
Avalyn Appoints Jon Congleton, Seasoned Biopharmaceutical Executive, to its Board of Directors
From Avalyn Pharma Inc.
Via GlobeNewswire
News headline image
Avalyn Announces Publication Demonstrating Correlation Between Imaging, Improved Lung Function, and Quality of Life with AP01 in Patients with Idiopathic Pulmonary Fibrosis
From Avalyn Pharma Inc.
Via GlobeNewswire
News headline image
Avalyn Announces First Patient Dosed in AURA Phase 2 Clinical Trial Evaluating AP02, Inhaled Nintedanib, for the Treatment of Idiopathic Pulmonary Fibrosis
From Avalyn Pharma Inc.
Via GlobeNewswire
News headline image
Avalyn Appoints Biopharmaceutical Industry Leader Kate Haviland to Board of Directors
From Avalyn Pharma Inc.
Via GlobeNewswire
News headline image
Avalyn to Present at the 44th Annual J.P. Morgan Healthcare Conference
From Avalyn Pharma Inc.
Via GlobeNewswire
News headline image
Avalyn to Participate in Multiple Upcoming Investor Conferences in November
From Avalyn Pharma Inc.
Via GlobeNewswire
News headline image
Avalyn Announces Multiple Presentations at the Pulmonary Fibrosis Foundation (PFF) Summit 2025
From Avalyn Pharma Inc.
Via GlobeNewswire
News headline image
Avalyn Appoints Industry Veterans Jill Denning and Kimberley Cummings to Leadership
From Avalyn Pharma Inc.
Via GlobeNewswire
News headline image
Avalyn to Highlight AURA-IPF Phase 2 Clinical Trial Design for AP02, Inhaled Nintedanib, at the European Respiratory Society International Congress 2025
From Avalyn Pharma Inc.
Via GlobeNewswire
News headline image
Avalyn to Participate in Multiple Upcoming Investor Conferences in September
From Avalyn Pharma Inc.
Via GlobeNewswire
News headline image
Avalyn Completes Oversubscribed $100 Million Series D Financing to Further Advance Clinical Development of Novel Inhaled Therapies for Pulmonary Fibrosis
From Avalyn Pharma Inc.
Via GlobeNewswire
News headline image
Avalyn Announces Upcoming Presentation on its Lead Program AP01, Inhaled Pirfenidone, for the Treatment of Pulmonary Fibrosis at the European Congress of Rheumatology 2025
From Avalyn Pharma Inc.
Via GlobeNewswire
News headline image
Avalyn to Participate in the Jefferies Global Healthcare Conference in June
From Avalyn Pharma Inc.
Via GlobeNewswire
News headline image
Avalyn Showcases Clinical Data Across Multiple Pulmonary Fibrosis Programs at ATS 2025
From Avalyn Pharma Inc.
Via GlobeNewswire
News headline image
Avalyn Announces Multiple Presentations on AP01 and AP02 for Pulmonary Fibrosis at the American Thoracic Society 2025 International Conference
From Avalyn Pharma Inc.
Via GlobeNewswire
News headline image
Avalyn to Participate in Upcoming Investor Conference in April
From Avalyn Pharma Inc.
Via GlobeNewswire
News headline image
Avalyn Completes Successful Phase 1 Clinical Trials of AP02, its Novel Inhaled Formulation of Nintedanib, Preparing for Phase 2 Development in Idiopathic Pulmonary Fibrosis
From Avalyn Pharma Inc.
Via GlobeNewswire
News headline image
Avalyn to Participate in TD Cowen 45th Annual Health Care Conference
From Avalyn Pharma Inc.
Via GlobeNewswire
News headline image
Avalyn to Present at the 43rd Annual J.P. Morgan Healthcare Conference
From Avalyn Pharma Inc.
Via GlobeNewswire
News headline image
Avalyn to Participate in Multiple Upcoming Investor Conferences
From Avalyn Pharma Inc.
Via GlobeNewswire
News headline image
Avalyn Appoints Heather Turner, J.D., Biopharma Industry Veteran, as Chair of its Board of Directors
From Avalyn Pharma Inc.
Via GlobeNewswire
News headline image
Avalyn to Participate in Multiple Upcoming Investor Conferences
From Avalyn Pharma Inc.
Via GlobeNewswire
News headline image
Avalyn CEO Lyn Baranowski Named a PharmaVoice 100 Honoree
From Avalyn Pharma Inc.
Via GlobeNewswire
News headline image
Avalyn Announces Upcoming Presentations on its Lead Program AP01, Inhaled Pirfenidone, for the Treatment of Pulmonary Fibrosis at the 22nd International Colloquium on Lung and Airway Fibrosis
From Avalyn Pharma Inc.
Via GlobeNewswire
< Previous 1 2 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.
TOP
Email a Story